Viral responses to EBV-specific T cells
| Pt. no. . | Viral disease . | Previous standard therapy . | Line infused . | HLA match (low-resolution) to recipient . | No. of infusions . | Best response by 6 wk . | Comments . |
|---|---|---|---|---|---|---|---|
| 16 | EBV | Rituximab (tumor later found to be CD20 negative) | C2274 | 2/6 | 3 | CR | CR EBV-PTLD based on imaging |
| 19 | EBV | Rituximab | C3366 C2270 | 2/6 | 3 | PR | CR based on viral load PR peripheral disease and stable CNS disease at 5 wk based on imaging when removed from study because of relapse of AML |
| 1/6 | |||||||
| 24 | EBV | Rituximab | C3629 | 1/6 | 1 | NR | Decrease in EBV-DNA followed by a chronic GVHD flare treated with steroids. Died of EBV lymphoma |
| 37 | EBV | Rituximab | C3617 | 3/6 | 1 | CR | CR EBV-PTLD based on imaging |
| 43 | EBV | Rituximab | C3005 | 1/6 | 1 | PR | Very good PR based on imaging |
| 47* | EBV (AdV) | Rituximab | C2339 (C2654) | 1/6 | 5 (1) | PR (CR) | Five infusions for EBV-PTLD with CR after 6 wk based on imaging and viral loads (subsequent emergency use of VST infusion for AdV followed by CR) |
| (1/6) | |||||||
| 74 | EBV | Rituximab | C3365 C2582 | 3/6 | 2 | NR | Died of EBV lymphoma. Second line administered after confirming EBV-PTLD origin was in second, not first, CBU |
| 1/6 | |||||||
| 79 | EBV | Rituximab | C3617 | 2/6 | 3 | PR | Transient PRs then recurrences, subsequent CR by viral load after infusion of donor-derived EBV-specific T cells |
| 90 | EBV | Rituximab | C2339 | 3/6 | 1 | NR | Died of EBV lymphoma |
| Pt. no. . | Viral disease . | Previous standard therapy . | Line infused . | HLA match (low-resolution) to recipient . | No. of infusions . | Best response by 6 wk . | Comments . |
|---|---|---|---|---|---|---|---|
| 16 | EBV | Rituximab (tumor later found to be CD20 negative) | C2274 | 2/6 | 3 | CR | CR EBV-PTLD based on imaging |
| 19 | EBV | Rituximab | C3366 C2270 | 2/6 | 3 | PR | CR based on viral load PR peripheral disease and stable CNS disease at 5 wk based on imaging when removed from study because of relapse of AML |
| 1/6 | |||||||
| 24 | EBV | Rituximab | C3629 | 1/6 | 1 | NR | Decrease in EBV-DNA followed by a chronic GVHD flare treated with steroids. Died of EBV lymphoma |
| 37 | EBV | Rituximab | C3617 | 3/6 | 1 | CR | CR EBV-PTLD based on imaging |
| 43 | EBV | Rituximab | C3005 | 1/6 | 1 | PR | Very good PR based on imaging |
| 47* | EBV (AdV) | Rituximab | C2339 (C2654) | 1/6 | 5 (1) | PR (CR) | Five infusions for EBV-PTLD with CR after 6 wk based on imaging and viral loads (subsequent emergency use of VST infusion for AdV followed by CR) |
| (1/6) | |||||||
| 74 | EBV | Rituximab | C3365 C2582 | 3/6 | 2 | NR | Died of EBV lymphoma. Second line administered after confirming EBV-PTLD origin was in second, not first, CBU |
| 1/6 | |||||||
| 79 | EBV | Rituximab | C3617 | 2/6 | 3 | PR | Transient PRs then recurrences, subsequent CR by viral load after infusion of donor-derived EBV-specific T cells |
| 90 | EBV | Rituximab | C2339 | 3/6 | 1 | NR | Died of EBV lymphoma |
AML, acute myeloid leukemia; CBU, cord blood unit; CNS, central nervous system. Other previously used abbreviations are explained in Table 2.
Subsequently went on to have an AdV infection and received a different VST line as emergency treatment after approval by the US Food and Drug Administration.